MET and/or ALK Inhibitors?
Does anyone have any experience with MET and/or ALK inhibitors for pancreatic cancer? Based on my father's molecular profiling, he is KRAS wildtype, and I've seen some published literature about the use of these (e.g. ceritinib) in this patient population. Thanks!
Interested in more discussions like this? Go to the Pancreatic Cancer Support Group.
I wonder if @patel @patti303 or @k13 might have something to add to this discussion.
@brittbk, has your dad's team mention that he may be a candidate for MET and/or ALK inhibitors as a treatment option?